| 主題 |
日期
(日/月/年) |
| 這連結會以新視窗打開保持警覺預防基孔肯雅熱 - 新增一宗居於上環的本地個案及本地最新情況 (只備英文版) |
04-12-2025 |
| 這連結會以新視窗打開Braftovi (encorafenib): Assessing the Potential Risk of Severe Cutaneous Adverse Reactions (Letter to Healthcare Professionals) (只備英文版) |
28-11-2025 |
| 這連結會以新視窗打開手足口病活躍程度維持在高水平 (只備英文版) |
21-11-2025 |
| 這連結會以新視窗打開保持警覺預防基孔肯雅熱 - 新增一宗居於東區的本地個案 (只備英文版) |
14-11-2025 |
| 這連結會以新視窗打開一宗居於青衣的基孔肯雅熱本地個案 (只備英文版) |
4-11-2025 |
| 這連結會以新視窗打開香港首宗基孔肯雅熱本地個案 (只備英文版) |
26-10-2025 |
| 這連結會以新視窗打開 保持警覺預防基孔肯雅熱及季節性流感 (只備英文版) |
22-10-2025 |
| 這連結會以新視窗打開基孔肯雅熱的最新狀況 (只備英文版) |
29-9-2025 |
| 這連結會以新視窗打開Announcements on the use of Paracetamol (also known as Acetaminophen) during pregnancy released by the World Health Organization and overseas drug regulatory authorities (只備英文版) |
26-9-2025 |
| 這連結會以新視窗打開FDA Responds to Evidence of Possible Association Between Autism and Acetaminophen (Paracetamol) Use During Pregnancy (只備英文版) |
23-9-2025 |
| 這連結會以新視窗打開提高警覺預防手足口病 (只備英文版) |
18-9-2025 |
| 這連結會以新視窗打開香港進入2025夏季流感季節 (只備英文版) |
10-9-2025 |
| 這連結會以新視窗打開Tegretol (carbamazepine): use restricted in neonates as concentration of one excipient, propylene glycol, exceeds recommended threshold (Letter to Healthcare Professionals) (只備英文版) |
8-9-2025 |
| 這連結會以新視窗打開Caspofungin: new warning against use of polyacrylonitrile-based membranes during continuous renal replacement therapy (Letter to Healthcare Professionals) (只備英文版) |
8-9-2025 |
| 這連結會以新視窗打開Polivy (polatuzumab vedotin): New identified risk of severe infusion site extravasation events (Letter to Healthcare Professionals) (只備英文版) |
5-9-2025 |
| 這連結會以新視窗打開Lipidem® 200mg/ml Emulsion for Infusion (10 x 500 ml): Important information on subvisual agglomerates and the need to use an infusion filter for fat emulsions (Letter to Healthcare Professionals) (只備英文版) |
4-9-2025 |
| 這連結會以新視窗打開FDA to recommend additional, earlier MRI monitoring for patients with Alzheimer’s disease taking Leqembi (lecanemab) (Letter to Healthcare Professionals) (只備英文版) |
29-8-2025 |
| 這連結會以新視窗打開Important safety information on CRYSVITA (burosumab) and the risk of severe hypercalcemia in patients with tertiary hyperparathyroidism (Letter to Healthcare Professionals) (只備英文版) |
26-8-2025 |
| 這連結會以新視窗打開基孔肯雅熱的最新狀況 (只備英文版) |
14-8-2025 |
| 這連結會以新視窗打開基孔肯雅熱的最新狀況及檢測安排 (只備英文版) |
9-8-2025 |
| 這連結會以新視窗打開香港基孔肯雅熱的最新狀況 (只備英文版) |
7-8-2025 |
| 這連結會以新視窗打開就首宗輸入個案 提高警覺預防基孔肯雅熱 (只備英文版) |
3-8-2025 |
| 這連結會以新視窗打開提高警覺預防基孔肯雅熱 (只備英文版) |
25-7-2025 |
| 這連結會以新視窗打開有關當值衞生主任的緊急聯絡方式由傳呼機更改為電話的事宜（只備英文版） |
25-7-2025 |
| 這連結會以新視窗打開廣東基孔肯雅熱爆發情況 (只備英文版) |
16-7-2025 |
| 這連結會以新視窗打開有關肝癌及鼻咽癌篩查的更新建議（只備英文版） |
14-7-2025 |
| 這連結會以新視窗打開Gadolinium-based Contrast Agents: Assessing the potential risk of serious adverse reactions, including seizures, encephalopathy, coma and death, with intrathecal use (Letter to Healthcare Professionals) (只備英文版) |
27-6-2025 |
| 這連結會以新視窗打開FDA approves required updated warning in labeling of mRNA COVID-19 Vaccines regarding myocarditis and pericarditis following vaccination (Letter to Healthcare Professionals) (只備英文版) |
26-6-2025 |
| 這連結會以新視窗打開第六版《效果》抗菌素指引已發布 (只備英文版) |
19-6-2025 |
| 這連結會以新視窗打開Valproate (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono or Chronosphere, Episenta, Epival, and Syonell▼): updated safety and educational materials to support patient discussion on reproductive risks (Letter to Healthcare Professionals) (只備英文版) |
11-6-2025 |
| 這連結會以新視窗打開European Union: PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy (Letter to Healthcare Professionals) (只備英文版) |
9-6-2025 |
| 這連結會以新視窗打開European Union: Changes to the use of antibiotic azithromycin (Letter to Healthcare Professionals) (只備英文版) |
26-5-2025 |
| 這連結會以新視窗打開FDA requires warning about rare but severe itching after stopping long-term use of oral allergy medicines cetirizine or levocetirizine (Zyrtec, Xyzal, and other trade names) (只備英文版) |
19-5-2025 |
| 這連結會以新視窗打開Measures to minimise risk of suicidal thoughts with finasteride and dutasteride medicines (Letter to Healthcare Professionals) (只備英文版) |
9-5-2025 |
| 這連結會以新視窗打開呼籲就海外國家麻疹個案上升提高警覺 (只備英文版) |
29-4-2025 |
| 這連結會以新視窗打開Cyclin-dependent kinase inhibitors (abemaciclib, palbociclib and ribociclib) and HMG-CoA reductase inhibitors (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin) (Statins): Assessing the potential risk of rhabdomyolysis due to drug interaction (Letter to Healthcare Professionals) (只備英文版) |
25-4-2025 |
| 這連結會以新視窗打開提高警覺 預防2019冠狀病毒病 (只備英文版) |
25-4-2025 |
| 這連結會以新視窗打開EMA concludes review of weight management medicine Mysimba (naltrexone / bupropion) - Benefits continue to outweigh risks, with new risk minimisation measures and more information to be provided about long-term effect on the heart (Letter to Healthcare Professionals) (只備英文版) |
31-3-2025 |
| 這連結會以新視窗打開Isotretinoin: Assessing the potential risk of sacroiliitis (Letter to Healthcare Professionals) (只備英文版) |
28-3-2025 |
| 這連結會以新視窗打開Oral anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban and warfarin): Assessing the potential risk of splenic rupture (Letter to Healthcare Professionals) (只備英文版) |
28-3-2025 |
| 這連結會以新視窗打開Prolonged-release opioids: Removal of indication for relief of post-operative pain (Letter to Healthcare Professionals) (只備英文版) |
13-3-2025 |
| 這連結會以新視窗打開疫苗可預防疾病科學委員會就使用呼吸道合胞病毒疫苗的暫擬共識 (只備英文版) |
20-1-2025 |
| 這連結會以新視窗打開香港2024/25流感季節來臨 (只備英文版) |
9-1-2025 |
| 這連結會以新視窗打開提高警覺預防急性腸胃炎 (只備英文版) |
9-1-2025 |
| 這連結會以新視窗打開FDA requires Guillain-Barré Syndrome (GBS) warning in the prescribing information for RSV Vaccines Abrysvo and Arexvy (Letter to Healthcare Professionals) (只備英文版) |
8-1-2025 |
| 這連結會以新視窗打開Potential risk of psychiatric withdrawal events with domperidone for stimulation of lactation (Letter to Healthcare Professionals) (只備英文版) |
31-12-2024 |
| 這連結會以新視窗打開Ilaris (canakinumab): Assessing the potential risk of drug reaction with eosinophilia and systemic symptoms (Letter to Healthcare Professionals) (只備英文版) |
20-12-2024 |
| 這連結會以新視窗打開一宗本地感染登革熱個案 (只備英文版) |
29-11-2024 |
| 這連結會以新視窗打開Promethazine hydrochloride (Phenergan) not to be used in children under 6 (Letter to Healthcare Professionals) (只備英文版) |
20-11-2024 |
| 這連結會以新視窗打開Tegretol Oral Suspension 2%: Update to the posology, method of administration, and limitation of use in neonates (Letter to Healthcare Professionals) (只備英文版) |
13-11-2024 |
| 這連結會以新視窗打開Olanzapine: Assessing the potential risks of syndrome of inappropriate secretion of antidiuretic hormone and hyponatremia (Letter to Healthcare Professionals) (只備英文版) |
1-11-2024 |
| 這連結會以新視窗打開Gavreto® (pralsetinib): New warning and precaution of severe and fatal infections (Letter to Healthcare Professionals) (只備英文版) |
30-10-2024 |
| 這連結會以新視窗打開提高警覺預防手足口病 (只備英文版) |
9-10-2024 |
| 這連結會以新視窗打開 在假期間提高警覺預防登革熱 (只備英文版) |
2-10-2024 |
| 這連結會以新視窗打開Summary Safety Review - Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the potential risks of prolonged or incident diabetic ketoacidosis despite stopping treatment in adult patients with type 2 diabetes (Letter to Healthcare Professionals) (只備英文版) |
27-9-2024 |
| 這連結會以新視窗打開Plaquenil® (Hydroxychloroquine sulfate): Risk of major congenital malformations and new risks of phospholipidosis and aggravation of myasthenia gravis symptoms (Letter to Healthcare Professionals) (只備英文版) |
20-9-2024 |
| 這連結會以新視窗打開Vigilance against Invasive Group B Streptococcus Infection (只備英文版) |
14-9-2024 |
| 這連結會以新視窗打開Lunsumio (mosunetuzumab): New important identified risk of Hemophagocytic Lymphohistiocytosis (Letter to Healthcare Professionals) (只備英文版) |
13-9-2024 |
| 這連結會以新視窗打開EMA recommends measures to minimise the risk of meningioma with medicines containing medroxyprogesterone acetate (Letter to Healthcare Professionals) (只備英文版) |
9-9-2024 |
| 這連結會以新視窗打開一宗本地感染登革熱個案 (只備英文版) |
17-8-2024 |
| 這連結會以新視窗打開世界衞生組織宣布猴痘疫情為國際關注的突發公共衞生事件 (只備英文版) |
15-8-2024 |
| 這連結會以新視窗打開Azithromycin and rare risk of cardiovascular death (Letter to Healthcare Professionals) (只備英文版) |
2-8-2024 |
| 這連結會以新視窗打開EMA advises about risks of using weight loss medicine Mysimba with opioids (Letter to Healthcare Professionals) (只備英文版) |
29-7-2024 |
| 這連結會以新視窗打開Thematic Report on Iron Status (Population Health Survey 2020-22) (只備英文版) |
16-7-2024 |
| 這連結會以新視窗打開New recommendations for GLP-1 receptor agonists to minimise risk of aspiration and pneumonia aspiration during general anaesthesia or deep sedation (Letter to Healthcare Professionals) (只備英文版) |
15-7-2024 |
| 這連結會以新視窗打開Nexavar (sorafenib): Assessing the potential risk of tumour lysis syndrome (Letter to Healthcare Professionals) (只備英文版) |
28-6-2024 |
| 這連結會以新視窗打開Warfarin: be alert to the risk of drug interactions with tramadol (Letter to Healthcare Professionals) (只備英文版) |
21-6-2024 |
| 這連結會以新視窗打開一宗可能在本地感染的登革熱個案 (只備英文版) |
19-6-2024 |
| 這連結會以新視窗打開CAR T-cell medicines: PRAC identifies risk of secondary malignancies of T-cell origin (Letter to Healthcare Professionals) (只備英文版) |
17-6-2024 |
| 這連結會以新視窗打開 呼籲就百日咳個案增加提高警覺 (只備英文版) |
24-5-2024 |
| 這連結會以新視窗打開本地季節性流感最新情況 (只備英文版) |
2-5-2024 |
|
這連結會以新視窗打開CHMP recommended new contraindications on the co-administration of Reyataz (Atazanavir) with encorafenib and ivosidenib, and with carbamazepine, phenobarbital, and phenytoin (Letter to Healthcare Professionals) (只備英文版) |
29-4-2024 |
| 這連結會以新視窗打開今年首宗本地感染的登革熱個案 (只備英文版) |
26-4-2024 |
| 這連結會以新視窗打開Vigilance against B virus infection and addition of the infection to the list of “Other communicable diseases of topical public health concern” (只備英文版) |
5-4-2024 |
| 這連結會以新視窗打開Ezetrol (ezetimibe) and the risks of drug-induced liver injury and severe cutaneous adverse reactions (Letter to Healthcare Professionals) (只備英文版) |
28-3-2024 |
|
這連結會以新視窗打開Amiodarone: Assessing the potential risk of primary graft dysfunction following heart transplantation (Letter to Healthcare Professionals) (只備英文版)
|
28-3-2024 |
| 這連結會以新視窗打開Ibrance (palbociclib): Assessing the potential risk of venous thromboembolism (Letter to Healthcare Professionals) (只備英文版) |
28-3-2024 |
| 這連結會以新視窗打開Updated warnings of faricimab (Vabysmo): retinal vasculitis risk (Letter to Healthcare Professionals) (只備英文版) |
21-3-2024 |
| 這連結會以新視窗打開Colistin (colistimethate sodium): Assessing the potential risk of pseudo-Bartter syndrome (Letter to Healthcare Professionals)(只備英文版) |
1-3-2024 |
| 這連結會以新視窗打開Vigilance against upsurge of measles(只備英文版) |
29-2-2024 |
| 這連結會以新視窗打開Vigilance against ceftriaxone reduced susceptible Neisseria gonorrhoeae infection |
30-1-2024 |
| 這連結會以新視窗打開Safety-related information for the product Mifegyne (Letter to Healthcare Professionals) (只備英文版) |
25-1-2024 |
| 這連結會以新視窗打開含mifepristone成分藥品安全資訊 (Letter to Healthcare Professionals) |
24-1-2024 |
| 這連結會以新視窗打開BCMA- and CD19-directed genetically modified autologous chimeric antigen receptor (CAR) T cell immunotherapies: risk of T cell malignancies (Letter to Healthcare Professionals) (只備英文版) |
24-1-2024 |
| 這連結會以新視窗打開Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate in the United Kingdom (Letter to Healthcare Professionals) (只備英文版) |
23-1-2024 |
| 這連結會以新視窗打開Arrival of the 2023/24 Winter Influenza Season in Hong Kong |
11-1-2024 |